By Colin Kellaher
Shares of Dyne Therapeutics took flight in premarket trading Wednesday after the clinical-stage muscle-disease company reported positive initial data from a pair of Phase 1/2 studies of its lead product candidates.
Dyne shares, which closed Tuesday at $13.06, were recently up 80% to $23.50 in premarket trading.
Dyne said DYNE-101 showed early dose-dependent results in a study of patients with myotonic dystrophy type 1, including in correction of the key biomarker splicing and meaningful improvement in myotonia at the lowest dose.
The Waltham, Mass., company said treatment with DYNE-251 in a separate study in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping surpassed the level of dystrophin production reported for the standard of care with a fraction of the dose.
Dyne said the study data from the two programs demonstrate proof-of-concept and validate the promise of its Force platform in developing targeted therapeutics for rare muscle diseases.
The company said it expects to report data for multiple higher-dose cohorts from both trials in the second half of 2024, adding that it aims to initiate registrational cohorts toward the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
Read the full article here
